Dynavax Technologies Corporation Total Liabilities
Dynavax Technologies Corporation total liabilities. Based on the latest financial reports, Dynavax Technologies Corporation (DVAX) has total liabilities worth $412.37 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Dynavax Technologies Corporation fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Dynavax Technologies Corporation (2000–2024)
Total liabilities of Dynavax Technologies Corporation from 2000 to 2024. This chart illustrates how Dynavax Technologies Corporation's total liabilities have evolved over time, based on quarterly financial data. Check Dynavax Technologies Corporation (DVAX) asset resilience to evaluate the company's liquid asset resilience ratio.
Dynavax Technologies Corporation Competitors by Total Liabilities
The table below lists competitors of Dynavax Technologies Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iluka Resources Ltd
AU:ILU
|
Australia | AU$2.16 Billion |
|
Mayora Indah Tbk
JK:MYOR
|
Indonesia | Rp13.61 Trillion |
|
Sunway Real Estate Investment Trust
KLSE:5176
|
Malaysia | RM5.29 Billion |
|
ARMOUR Residential REIT Inc
NYSE:ARR
|
USA | $20.17 Billion |
|
Semapa
LS:SEM
|
Portugal | €3.38 Billion |
|
A.F.P. Provida
SN:PROVIDA
|
Chile | CL$206.75 Billion |
|
NCAB Group
ST:NCAB
|
Sweden | Skr2.08 Billion |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $14.95 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Dynavax Technologies Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Dynavax Technologies Corporation total assets.
Liquidity & Leverage Metrics
Dynavax Technologies Corporation Total Liabilities Ratios Explained
Dynavax Technologies Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dynavax Technologies Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dynavax Technologies Corporation (2000–2024)
The table below shows the annual total liabilities of Dynavax Technologies Corporation from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $389.46 Million | +3.85% |
| 2023-12-31 | $375.02 Million | -7.36% |
| 2022-12-31 | $404.84 Million | -50.44% |
| 2021-12-31 | $816.87 Million | +177.30% |
| 2020-12-31 | $294.58 Million | +8.79% |
| 2019-12-31 | $270.78 Million | +83.18% |
| 2018-12-31 | $147.82 Million | +668.45% |
| 2017-12-31 | $19.24 Million | -6.07% |
| 2016-12-31 | $20.48 Million | -30.71% |
| 2015-12-31 | $29.55 Million | -21.83% |
| 2014-12-31 | $37.81 Million | +106.29% |
| 2013-12-31 | $18.33 Million | -26.47% |
| 2012-12-31 | $24.93 Million | -27.16% |
| 2011-12-31 | $34.22 Million | +6.48% |
| 2010-12-31 | $32.14 Million | -27.11% |
| 2009-12-31 | $44.09 Million | -40.79% |
| 2008-12-31 | $74.47 Million | -8.42% |
| 2007-12-31 | $81.32 Million | +241.41% |
| 2006-12-31 | $23.82 Million | +315.67% |
| 2005-12-31 | $5.73 Million | -58.39% |
| 2004-12-31 | $13.77 Million | -84.49% |
| 2003-12-31 | $88.78 Million | +1.06% |
| 2002-12-31 | $87.85 Million | +77.35% |
| 2001-12-31 | $49.53 Million | +4.09% |
| 2000-12-31 | $47.59 Million | -- |
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more